Bionexus Gene Lab CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
BioNexus Gene Lab Corp. filed its Q2 2026 report, detailing a substantial decrease in revenue and continued operational losses, while also addressing internal control deficiencies and strategic initiatives.
NASDAQ
BioNexus Gene Lab Corp. reports a significant revenue decline for Q1 2026 amid internal control remediation and legal action against former management.
NASDAQ
BioNexus Gene Lab Corp. reports a wider net loss for the nine months ended September 30, 2025, while pursuing strategic shifts into biotech CDMO and digital asset treasury.
NASDAQ
BioNexus Gene Lab Corp. reported a significant net loss for the six months ended June 30, 2025, as it pivots towards biotechnology CDMO, expands genomic screening, and adopts an Ethereum treasury strategy.
NASDAQ
BioNexus Gene Lab Corp. announces its Q1 2025 financial results, highlighting a strategic shift towards digital assets and addressing Nasdaq compliance while experiencing a revenue decrease.
NASDAQ
BioNexus Gene Lab Corp. reports a net loss for Q3 2024, alongside ongoing internal investigations and a Nasdaq delisting notice.
NASDAQ
BioNexus Gene Lab Corp. saw a decrease in revenue but an increase in profitability for the second quarter of 2024, compared to the same period last year.
NASDAQ
BioNexus Gene Lab Corp. has filed an amendment to its quarterly report to address deficiencies in its disclosure controls and procedures.
NASDAQ
BioNexus Gene Lab Corp. has filed an amendment to its quarterly report to address a comment from the SEC regarding the effectiveness of its disclosure controls and procedures.
NASDAQ
10-Q/A: BioNexus Gene Lab Corp. Files Amended Quarterly Report, Acknowledges Ineffective Disclosure Controls
BioNexus Gene Lab Corp. has amended its Form 10-Q for the quarter ended March 31, 2023, to address ineffective disclosure controls and procedures, as identified in a comment letter from the SEC.
NASDAQ
BioNexus Gene Lab Corp. reports a net loss of $103,757 for the first quarter of 2024, with a slight increase in revenue compared to the same period last year.
NASDAQ
BioNexus Gene Lab Corp. reports a slight decrease in revenue and a significant increase in operating expenses for the third quarter of 2023, primarily due to costs associated with its Nasdaq listing.